吉西他滨：在治疗晚期非鳞状非小细胞肺癌中的疗效。
Gemcitabine: efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancer.
机构信息
Department of Medical Oncology, Kinki University School of Medicine, Osaka-Sayama, Japan.
出版信息
Clin Med Insights Oncol. 2011;5:177-84. doi: 10.4137/CMO.S6252. Epub 2011 May 29.
Abstract
Lung cancer is the leading cause of cancer-related death in many countries. Approximately half of the patients with non-small cell lung cancer have advanced disease and systemic chemotherapy, especially platinum-based doublets, is currently the standard treatment. Several trials have recently indicated the importance of histological subtype for treatment with molecular target chemotherapy and pemetrexed. Over the last decade, gemcitabine, a pyrimidine nucleoside antimetabolite, has been one of the most effective agents for patients with advanced non-small cell lung cancer. It is unknown whether histological type is a predictor of the outcome of treatment with this agent. This is a review of the past trials and reviews of first-line treatment for advanced NSCLC, focusing on efficacy and safety of treatment with gemcitabine according to histological subtype.
摘要
肺癌是许多国家癌症相关死亡的主要原因。大约一半的非小细胞肺癌患者患有晚期疾病，目前标准治疗方法是全身化疗，特别是铂类双联化疗。最近的几项试验表明，组织学亚型对于分子靶向化疗和培美曲塞的治疗很重要。在过去的十年中，嘧啶核苷类似物吉西他滨一直是晚期非小细胞肺癌患者最有效的药物之一。目前尚不清楚组织学类型是否是该药物治疗结果的预测因素。这是对过去试验和晚期 NSCLC 一线治疗的综述，重点是根据组织学亚型评估吉西他滨治疗的疗效和安全性。
相似文献
1
Gemcitabine: efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancer.吉西他滨：在治疗晚期非鳞状非小细胞肺癌中的疗效。
Clin Med Insights Oncol. 2011;5:177-84. doi: 10.4137/CMO.S6252. Epub 2011 May 29.
2
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.MILES-3和MILES-4研究的基本原理与设计：两项随机3期试验，比较单药化疗与以顺铂为基础的双药联合化疗用于老年晚期非小细胞肺癌患者的疗效。
Clin Lung Cancer. 2014 Mar;15(2):166-70. doi: 10.1016/j.cllc.2013.11.011. Epub 2013 Nov 20.
3
Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer.一线全身治疗晚期非小细胞肺癌患者的治疗模式和总生存情况。
J Manag Care Spec Pharm. 2017 Feb;23(2):195-205. doi: 10.18553/jmcp.2017.23.2.195.
4
Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.培美曲塞/顺铂对比吉西他滨/顺铂作为中国晚期非鳞状非小细胞肺癌患者一线治疗的疗效和安全性
Lung Cancer. 2014 Sep;85(3):401-7. doi: 10.1016/j.lungcan.2014.07.007. Epub 2014 Jul 17.
5
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.三项 III 期临床试验的组织学分层治疗分析显示培美曲塞在非鳞状非小细胞肺癌中的优势。
J Thorac Oncol. 2011 Jan;6(1):64-70. doi: 10.1097/JTO.0b013e3181f7c6d4.
6
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, histology and response to previous induction.贝叶斯网络荟萃分析在一线诱导化疗后疾病未进展且体能状态良好的 IIIb/IV 期非小细胞肺癌（NSCLC）患者中维持治疗的疗效：基于体能状态、EGFR 突变、组织学和对前序诱导治疗的反应的结果
Eur J Cancer. 2015 Nov;51(16):2330-44. doi: 10.1016/j.ejca.2015.07.007. Epub 2015 Sep 10.
7
Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.培美曲塞联合铂类一线治疗与其他铂类双联方案治疗老年东亚晚期非鳞状非小细胞肺癌的Meta分析
Clin Lung Cancer. 2016 Sep;17(5):e103-e112. doi: 10.1016/j.cllc.2016.04.003. Epub 2016 Apr 29.
8
[A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].一项比较培美曲塞/顺铂与吉西他滨/顺铂作为晚期非鳞状非小细胞肺癌一线治疗方案的随机、对照、多中心临床试验
Zhongguo Fei Ai Za Zhi. 2012 Oct;15(10):576-82. doi: 10.3779/j.issn.1009-3419.2012.10.03.
9
Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.培美曲塞联合铂类或吉西他滨联合铂类治疗晚期非小细胞肺癌：东亚地区多中心随机二期临床试验的最终生存分析及荟萃分析。
Respirology. 2013 Jan;18(1):131-9. doi: 10.1111/j.1440-1843.2012.02248.x.
10
Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials.培美曲塞联合顺铂与其他一线双药方案治疗晚期非小细胞肺癌（NSCLC）的比较：三项 III 期临床试验的联合分析。
Lung Cancer. 2012 May;76(2):222-7. doi: 10.1016/j.lungcan.2011.10.021. Epub 2011 Nov 23.
引用本文的文献
1
Machine learning-based characterization of a PANoptosis-associated model for enhancing prognosis and immunotherapy response in lung adenocarcinoma patients.基于机器学习的全程序死亡相关模型的特征分析，用于改善肺腺癌患者的预后和免疫治疗反应。
Discov Oncol. 2025 Aug 24;16(1):1605. doi: 10.1007/s12672-025-03456-5.
2
Encapsulation of Curcumin and Gemcitabine: Cytotoxic Effect and Mechanisms of Death in Lung Cancer.姜黄素与吉西他滨的包封：对肺癌的细胞毒性作用及死亡机制
Adv Pharmacol Pharm Sci. 2025 Aug 13;2025:8816364. doi: 10.1155/adpp/8816364. eCollection 2025.
3
Multimodality treatment approach in a patient with EGFR-mutated NSCLC and leptomeningeal metastases: A case report and literature review.表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）合并软脑膜转移患者的多模态治疗方法：一例报告及文献综述
Medicine (Baltimore). 2025 Jul 18;104(29):e43436. doi: 10.1097/MD.0000000000043436.
4
Preclinical experience with cisplatin, gemcitabine, and doxorubicin in pulmonary suffusion.顺铂、吉西他滨和阿霉素在肺灌洗中的临床前经验。
JTCVS Open. 2025 Jan 20;24:484-495. doi: 10.1016/j.xjon.2024.12.012. eCollection 2025 Apr.
5
The integrated stress response drives MET oncogene overexpression in cancers.整合应激反应促使癌症中MET癌基因的过表达。
EMBO J. 2025 Feb;44(4):1107-1130. doi: 10.1038/s44318-024-00338-4. Epub 2025 Jan 7.
6
Connecting dots between nucleotide biosynthesis and DNA lesion repair/bypass in cancer.在癌症中连接核苷酸生物合成与 DNA 损伤修复/绕过之间的联系。
Biosci Rep. 2024 Sep 25;44(9). doi: 10.1042/BSR20231382.
7
Investigation of Lung Cancer Cell Response to Cryoablation and Adjunctive Gemcitabine-Based Cryo-Chemotherapy Using the A549 Cell Line.使用A549细胞系研究肺癌细胞对冷冻消融及基于吉西他滨的辅助冷冻化疗的反应。
Biomedicines. 2024 Jun 3;12(6):1239. doi: 10.3390/biomedicines12061239.
8
A context-aware deconfounding autoencoder for robust prediction of personalized clinical drug response from cell-line compound screening.一种用于从细胞系化合物筛选中稳健预测个性化临床药物反应的上下文感知去混杂自动编码器。
Nat Mach Intell. 2022 Oct;4(10):879-892. doi: 10.1038/s42256-022-00541-0. Epub 2022 Oct 17.
9
Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer.非小细胞肺癌中的靶向表皮生长因子受体纳米疗法
J Funct Biomater. 2023 Sep 9;14(9):466. doi: 10.3390/jfb14090466.
10
Identification of fatty acid-related subtypes, the establishment of a prognostic signature, and immune infiltration characteristics in lung adenocarcinoma.肺腺癌中脂肪酸相关亚型的鉴定、预后特征模型的建立和免疫浸润特征。
Aging (Albany NY). 2023 May 16;15(10):4202-4235. doi: 10.18632/aging.204725.
本文引用的文献
1
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.组织学是否能预测接受铂类化疗的晚期非小细胞肺癌患者的生存情况？对东部肿瘤协作组研究 E1594 的分析。
Lung Cancer. 2013 Jul;81(1):47-52. doi: 10.1016/j.lungcan.2013.03.018. Epub 2013 Apr 21.
2
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.吉非替尼或化疗用于治疗具有突变型 EGFR 的非小细胞肺癌。
N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.
3
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.吉非替尼对比顺铂联合多西他赛用于治疗表皮生长因子受体突变的非小细胞肺癌患者（WJTOG3405）：一项开放标签、随机对照 3 期临床试验。
Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18.
4
The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.组织学在晚期非小细胞肺癌常用一线方案中的作用：三臂随机试验回顾性分析的简要报告。
J Thorac Oncol. 2009 Dec;4(12):1568-71. doi: 10.1097/JTO.0b013e3181c06980.
5
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.培美曲塞维持治疗联合最佳支持治疗与安慰剂联合最佳支持治疗用于非小细胞肺癌：一项随机、双盲、3期研究
Lancet. 2009 Oct 24;374(9699):1432-40. doi: 10.1016/S0140-6736(09)61497-5. Epub 2009 Sep 18.
6
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.顺铂联合吉西他滨加安慰剂或贝伐单抗作为非鳞状非小细胞肺癌一线治疗的III期试验：AVAil研究
J Clin Oncol. 2009 Mar 10;27(8):1227-34. doi: 10.1200/JCO.2007.14.5466. Epub 2009 Feb 2.
7
The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review.组织学在晚期非小细胞肺癌中的预后及预测作用：文献综述
J Thorac Oncol. 2008 Dec;3(12):1468-81. doi: 10.1097/JTO.0b013e318189f551.
8
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial.一项关于晚期非小细胞肺癌的国际多中心随机III期研究：一线使用厄洛替尼序贯二线使用顺铂/吉西他滨与一线使用顺铂/吉西他滨序贯二线使用厄洛替尼的对比——TORCH试验的治疗原理及方案动态
Clin Lung Cancer. 2008 Jul;9(4):235-8. doi: 10.3816/CLC.2008.n.037.
9
Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer.两剂培美曲塞联合叶酸和维生素B12用于既往治疗过的非小细胞肺癌患者的疗效和安全性
Clin Cancer Res. 2008 Jul 1;14(13):4206-12. doi: 10.1158/1078-0432.CCR-07-5143.
10
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.一项III期研究，比较顺铂加吉西他滨与顺铂加培美曲塞用于初治晚期非小细胞肺癌患者的化疗效果。
J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27.
Zotero 插件